These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 33669447

  • 61. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
    Turkmen E, Sogutlu F, Erdogan M, Biray Avci C.
    Med Oncol; 2023 Jun 07; 40(7):196. PubMed ID: 37284891
    [Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53.
    Li J, Zheng X, Gao M, Zhao J, Li Y, Meng X, Qian B, Li J.
    Oncol Rep; 2017 Jan 07; 37(1):458-464. PubMed ID: 28004113
    [Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.
    J Nucl Med; 2012 Nov 07; 53(11):1764-71. PubMed ID: 23055533
    [Abstract] [Full Text] [Related]

  • 68. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, Kiyonaga F, Kaneko N, Sasamata M.
    Clin Cancer Res; 2011 Aug 15; 17(16):5423-31. PubMed ID: 21737502
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70. Suppression of Rotenone-Treated Human Breast Cancer Stem Cell Survival Using Survivin Inhibitor YM155 is Associated to Oxidative Stress Modulation.
    Syahrani RA, Yunita E, Wanandi SI.
    Asian Pac J Cancer Prev; 2020 Sep 01; 21(9):2631-2637. PubMed ID: 32986362
    [Abstract] [Full Text] [Related]

  • 71. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella E, Gigantino V, Franco R, Marone G, Portella G.
    Oncotarget; 2016 Jan 12; 7(2):1500-15. PubMed ID: 26625205
    [Abstract] [Full Text] [Related]

  • 72. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F, Orlandi P, Paparo SR, Patrizio A, Piaggi S, La Motta C, Ulisse S, Baldini E, Materazzi G, Miccoli P, Antonelli A, Fallahi P.
    Oncol Rep; 2018 May 12; 39(5):2225-2234. PubMed ID: 29517103
    [Abstract] [Full Text] [Related]

  • 73. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI, Kim DK, Seo EJ, Choi EJ, Kwon YW, Jang IH, Lee JC, Kim HY, Shong M, Kim JH, Kim SJ.
    Thyroid; 2017 Nov 12; 27(11):1424-1432. PubMed ID: 28920531
    [Abstract] [Full Text] [Related]

  • 74. Antisense-miR-21 enhances differentiation/apoptosis and reduces cancer stemness state on anaplastic thyroid cancer.
    Haghpanah V, Fallah P, Tavakoli R, Naderi M, Samimi H, Soleimani M, Larijani B.
    Tumour Biol; 2016 Jan 12; 37(1):1299-308. PubMed ID: 26289851
    [Abstract] [Full Text] [Related]

  • 75. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K, Sato F, Tamagawa S, Gunduz M, Onoda N, Uchino S, Muragaki Y, Hotomi M.
    Sci Rep; 2019 Oct 10; 9(1):14616. PubMed ID: 31601917
    [Abstract] [Full Text] [Related]

  • 76. YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.
    Yan X, Su H.
    Med Sci Monit; 2017 Apr 24; 23():1963-1972. PubMed ID: 28435150
    [Abstract] [Full Text] [Related]

  • 77. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
    Tang J, Tian Z, Liao X, Wu G.
    Int J Biol Sci; 2021 Apr 24; 17(2):417-429. PubMed ID: 33613102
    [Abstract] [Full Text] [Related]

  • 78. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
    Saini S, Sripada L, Tulla K, Kumar P, Yue F, Kunda N, Maker AV, Prabhakar BS.
    Cell Death Dis; 2019 Feb 13; 10(2):145. PubMed ID: 30760700
    [Abstract] [Full Text] [Related]

  • 79. The Role of Notch1 Signaling in Anaplastic Thyroid Carcinoma.
    Kim HJ, Kim MJ, Kim A, Jung CW, Park S, Koh JS, Myung JK.
    Cancer Res Treat; 2017 Apr 13; 49(2):509-517. PubMed ID: 27586674
    [Abstract] [Full Text] [Related]

  • 80. USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.
    Chandrasekaran AP, Kaushal K, Park CH, Kim KS, Ramakrishna S.
    Theranostics; 2021 Apr 13; 11(20):9752-9771. PubMed ID: 34815782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.